Back to results
US 2012/0251487 A1Published application
Compounds and pharmaceutical compositions for the treatment of viral infections
AssigneeIdenix Pharmaceuticals, Inc.
InventorDominique SURLERAUX
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Claims62
A compound of Formula I:
- or a pharmaceutically acceptable salt, solvate, a stereoisomeric, tautomeric or polymorphic form thereof, wherein
- A is
- R is a moiety derivable by removal of a hydrogen from a hydroxy group of an antiviral drug, such as a nucleoside or nucleoside analog;
- X is O or S;
- Q is OR4, SR4 or NR5R6;
- each E is independently CR7R8;
- n is 1 or 2;
- Ry is alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, amino, aminoalkyl, hydroxyalkyl, heterocyclyl or heteroaryl, all optionally substituted;
- R1 and R2 are selected as follows:
- i) R1 and R2 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl;
- ii) R1 and R2 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring, wherein the ring is unsubstituted or substituted by C(O)Q1;
- or
- iii) R1 is hydrogen, alkyl or cycloalkyl, and R2 is (G)mC(O)Q1, wherein
- Q1 is OR4, SR4 or NR5R6;
- each G is independently CR7R8;
- and
- each m is 1 or 2;
- R3 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
- or when n is 1, R3 and R7 together with the nitrogen and carbon atoms to which they are attached form a 4-7 membered heterocyclic ring, wherein the ring is unsubstituted or substituted by C(O)Q1;
- R4 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
- R5 and R6 are selected as follows:
- i) R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
- or
- ii) R5 and R6 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring;
- and
- R7 and R8 are selected as follows:
- i) R7 and R8 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy;
- or
- ii) R7 and R8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring;
- and
- wherein if R2 is (G)mC(O)Q1, G is CR7R8;
- m is 1, and one of R7 or R8 is hydrogen, the other of R7 and R8 is not methyl.
29 more elements
A compound of Formula II:
- or a pharmaceutically acceptable salt, a stereoisomeric, tautomeric or polymorphic form thereof, wherein;
- Base is a substituted or unsubstituted purine or pyrimidine;
- W is alkyl, cycloalkyl, alkenyl, cycloalkenyl or alkynyl;
- X is O or S;
- Y is hydrogen or OR9;
- Z is hydrogen, OR10, SR10, NR5R6, F, Cl, Br or I;
- Q is OR4, SR4 or NR5R6;
- each E is independently CR7R8;
- each n is 1 or 2;
- R1 and R2 are selected as follows:
- i) R1 and R2 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl;
- ii) R1 and R2 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring, wherein the ring is unsubstituted or substituted by C(O)Q1;
- or
- iii) R1 is hydrogen, alkyl or cycloalkyl, and R2 is (G)mC(O)Q1, wherein
- Q1 is OR4, SR4 or NR5R6;
- each G is independently CR7R8;
- and
- each m is 1 or 2;
- R3 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
- or
- when n is 1, R3 and R7 together with the nitrogen and carbon atoms to which they are attached form a 4-7 membered heterocyclic ring, wherein the ring is unsubstituted or substituted by C(O)Q1;
- R4 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
- R5 and R6 are selected as follows:
- i) R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
- or
- ii) R5 and R6 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring;
- R7 and R8 are selected as follows:
- i) R7 and R8 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy;
- or
- ii) R7 and R8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring;
- R9 and R10 are selected as follows:
- i) R9 and R10 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
- or
- ii) R9 and R10 together with C(O) and the oxygen or sufur atoms on which they are substituted form a 5 membered ring.
31 more elements
Dependencies are inferred from the claim text.